...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil.
【24h】

Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil.

机译：富含（-）-棉酚的棉籽油对人乳腺癌细胞中多药耐药基因表达的调节。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Multidrug resistance (MDR) is a major impediment to successful cancer chemotherapy. P-glycoprotein (P-gp), the product of the multidrug resistance 1 (MDR1) gene, acts as an efflux pump and prevents sufficient intracellular accumulation of several anticancer agents, thus, playing a major role in MDR. Tamoxifen (Tam), ICI 182 780 (ICI) and Adriamycin (Adr) alone or with (-)-gossypol-enriched cottonseed oil [(-)-GPCSO] possible effects on cell growth inhibition and regulation of MDR1, mRNA and P-gp expression were examined in both an MDR human breast cancer cell line, MCF-7/Adr cells, and primary cultured human breast cancer epithelial cells (PCHBCEC). MATERIALS AND METHODS: Cells were treated with 0.05% of (-)-GPCSO either in the absence or presence of either 0.1 microM Tam, ICI or Adr for 24 h. RESULTS: Using the non-radioactive cell proliferation MTS assay, none of these chemotherapeutic agents alone inhibited MCF-7/Adr cell and PCHBCEC proliferation; meanwhile, the combination of 0.1 microM Tam, ICI or Adr with 0.05% (-)-GPCSO significantly reduced MCF-7/Adr cell growth by approximately 34%, 32% and 23%, respectively, of that of the vehicle-treated cells. For PCHBCEC, the combination of 0.05% (-)-GPCSO with 0.1 microM of Tam, ICI and Adr reduced cell growth to about 94%, 90%, and 71% respectively, of the vehicle treated PCHBCEC. Furthermore, (-)-GPCSO inhibited MDR1/P-gp expression in both MCF- 7/Adr and PCHBCEC in a dose-dependent manner. Our results provide insight into the MDR-reversing potential of (-)-GPCSO in human breast cancer cells resistant to current chemotherapeutic agents.
机译：背景：多药耐药性（MDR）是成功进行癌症化学疗法的主要障碍。 P-糖蛋白（P-gp）是多药抗性1（MDR1）基因的产物，可作为外排泵并阻止多种抗癌剂在细胞内的充分积累，因此在MDR中起主要作用。他莫昔芬（Tam），ICI 182780（ICI）和阿霉素（Adr）单独或与富含（-）-棉酚的棉籽油[（-）-GPCSO]可能对细胞生长的抑制以及MDR1，mRNA和P-的调节有关在MDR人乳腺癌细胞系MCF-7 / Adr细胞和原代培养的人乳腺癌上皮细胞（PCHBCEC）中都检查了gp表达。材料与方法：在不存在或存在0.1 microM Tam，ICI或Adr的情况下，将细胞用0.05％（-）-GPCSO处理24小时。结果：使用非放射性细胞增殖MTS测定法，这些化学治疗剂均未单独抑制MCF-7 / Adr细胞和PCHBCEC增殖。同时，将0.1 microM Tam，ICI或Adr与0.05％（-）-GPCSO组合使用时，MCF-7 / Adr细胞的生长分别比溶媒处理的细胞分别减少了约34％，32％和23％ 。对于PCHBCEC，将0.05％（-）-GPCSO与0.1 microM的Tam，ICI和Adr混合使用，可使细胞生长分别减少至经载体处理的PCHBCEC的约94％，90％和71％。此外，（-）-GPCSO以剂量依赖的方式抑制了MCF-7 / Adr和PCHBCEC中的MDR1 / P-gp表达。我们的结果提供了对（-）-GPCSO在对当前化学治疗剂具有抗性的人乳腺癌细胞中MDR逆转潜力的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号